N822K c-kit mutation in CD30-positive cutaneous pleomorphic mastocytosis after germ cell tumour of the ovary

British Journal of Dermatology

Volumn 166, Issue 6, 2012, Pages 1370-1373

  Baek, J O ^a   Kang, H K ^a   Na, S Y ^b   Lee, J R ^a   Roh, J Y ^a   Lee, J H ^a   Kim, H J ^c   Park, S ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BLEOMYCIN; CD30 ANTIGEN; CD4 ANTIGEN; CISPLATIN; ETOPOSIDE; GENOMIC DNA; IFOSFAMIDE; STEM CELL FACTOR; VINBLASTINE;

ADOLESCENT; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CUTANEOUS PLEOMORPHIC MASTOCYTOSIS; CYTOREDUCTIVE SURGERY; DEATH; EOSINOPHILIA; FEMALE; GENE MUTATION; GERM CELL TUMOR; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LETTER; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTOCYTOSIS; MISSENSE MUTATION; MONOCYTOSIS; MULTIPLE ORGAN FAILURE; MUTATIONAL ANALYSIS; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; SALPINGOOOPHORECTOMY; SKIN DEFECT; SPINDLE CELL;

ADOLESCENT; ANTIGENS, CD30; FEMALE; HUMANS; MASTOCYTOSIS, CUTANEOUS; MUTATION, MISSENSE; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84862792629     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10816.x     Document Type: Letter

References (10)

1. Ashman LK,. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999; 31: 1037-51.
2. Kitamura Y, Hirota S, Nishida T,. A loss-of-function mutation of c-kit results in depletion of mast cells and interstitial cells of Cajal, while its gain-of-function mutation results in their oncogenesis. Mutat Res 2001; 477: 165-71.
3. Rossi P, Sette C, Dolci S, Geremia R,. Role of c-kit in mammalian spermatogenesis. J Endocrinol Invest 2000; 23: 609-15.
4. Yoshida H, Takakura N, Kataoka H, et al. Stepwise requirement of c-kit tyrosine kinase in mouse ovarian follicle development. Dev Biol 1997; 184: 122-37.
5. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609-14.
6. Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA,. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999; 154: 1643-7.
7. Cheng L, Roth LM, Zhang S, et al. KIT gene mutation and amplification in dysgerminoma of the ovary. Cancer 2011; 117: 2096-103.
8. Tran DT, Jokinen CH, Argenyi ZB,. Histiocyte-rich pleomorphic mastocytoma: an uncommon variant mimicking juvenile xanthogranuloma and Langerhans cell histiocytosis. J Cutan Pathol 2009; 36: 1215-20.
9. Sotlar K, Cerny-Reiterer S, Petat-Dutter K, et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 2011; 24: 585-95.
10. Valent P, Sotlar K, Horny HP,. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma 2011; 52: 740-4.